000 | 01755 a2200445 4500 | ||
---|---|---|---|
005 | 20250515102752.0 | ||
264 | 0 | _c20080805 | |
008 | 200808s 0 0 eng d | ||
022 | _a1619-7070 | ||
024 | 7 |
_a10.1007/s00259-007-0659-z _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLam, Marnix G E H | |
245 | 0 | 0 |
_aCombined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. _h[electronic resource] |
260 |
_bEuropean journal of nuclear medicine and molecular imaging _cApr 2008 |
||
300 |
_a756-65 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aBone Density Conservation Agents _xadverse effects |
650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 |
_aDiphosphonates _xadverse effects |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImidazoles _xadverse effects |
650 | 0 | 4 | _aInjections, Intravenous |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMetabolic Clearance Rate |
650 | 0 | 4 | _aNeoplasm Metastasis |
650 | 0 | 4 |
_aOrganometallic Compounds _xadministration & dosage |
650 | 0 | 4 |
_aOrganophosphorus Compounds _xadministration & dosage |
650 | 0 | 4 |
_aProstatic Neoplasms _xpathology |
650 | 0 | 4 |
_aRadioisotopes _xadministration & dosage |
650 | 0 | 4 |
_aSamarium _xadministration & dosage |
650 | 0 | 4 | _aZoledronic Acid |
700 | 1 | _aDahmane, Amel | |
700 | 1 | _aStevens, Wil H M | |
700 | 1 | _avan Rijk, Peter P | |
700 | 1 | _ade Klerk, John M H | |
700 | 1 | _aZonnenberg, Bernard A | |
773 | 0 |
_tEuropean journal of nuclear medicine and molecular imaging _gvol. 35 _gno. 4 _gp. 756-65 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00259-007-0659-z _zAvailable from publisher's website |
999 |
_c17668901 _d17668901 |